Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
- Conditions
- Major Depressive DisorderInsomnia
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 87
- Registration Number
- NCT03771664
- Locations
- 🇺🇸
Sage Investigational Site, Austin, Texas, United States
A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT03764488
- Locations
- 🇺🇸
Research Site, New York, New York, United States
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
- Conditions
- Cognitive Impairment Associated With Schizophrenia
- Interventions
- Other: Placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 195
- Registration Number
- NCT03745820
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT03716570
- Locations
- 🇯🇵
Research Site, Kodaira-shi, Tokyo-To, Japan
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
- Conditions
- Bipolar Disorder IBipolar Disorder IIMajor Depressive Episode
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35
- Registration Number
- NCT03692910
- Locations
- 🇺🇸
Sage Investigational Site, Richardson, Texas, United States
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 585
- Registration Number
- NCT03689972
- Locations
- 🇧🇪
CHU de Tivoli, La Louvière, Belgium
🇺🇸MS Center of California, Laguna Hills, California, United States
🇺🇸UCI MIND, Irvine, California, United States
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 581
- Registration Number
- NCT03672175
- Locations
- 🇺🇸
Site Investigational Site, Decatur, Georgia, United States
🇺🇸Sage Investigational Site, Charlottesville, Virginia, United States
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
- Conditions
- Arthritis, PsoriaticArthritis, RheumatoidSpondylitis, AnkylosingCrohn's DiseaseColitis, Ulcerative
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2274
- Registration Number
- NCT03662919
- Locations
- 🇫🇷
Research Site, Toulon, Provence-Alpes-Côte d'Azur, France
🇫🇷Research Site 2, La Rochelle, Nouvelle-Aquitaine, France
🇫🇷Research Site 3, Paris, Ile De France, France
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
- Conditions
- Alzheimer's DiseaseCognitive Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT03639987
- Locations
- 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸Pacific Research Network, Inc, San Diego, California, United States
🇺🇸Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Biogen
- Registration Number
- NCT03637387